Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 70/100

Altimmune to Participate at Two Upcoming Investor Conferences

Wednesday, May 29, 2024 1 min read
Key Takeaway: Altimmune, Inc. has announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference on June 5, 2024, and the Goldman Sachs Global Healthcare Conference on June 12, 2024. Members of the management team will be available for individual meetings, showcasing the company's efforts to engage with investors. The events will feature webcasts accessible through the Altimmune website, highlighting the company's focus on its innovative pipeline, particularly in developing peptide-based therapeutics for obesity and MASH.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in prominent investor conferences demonstrates strong investor engagement.
  • Management team's availability for 1x1 meetings indicates openness and transparency.
  • Focus on innovative therapeutic developments reflects a commitment to advancement in healthcare.

Full Press Release Details

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
Jefferies Global Healthcare Conference (New York, NY)
Wednesday, June 5, 2024
Fireside Chat at 2:00 p.m. Eastern Time
Goldman Sachs Global Healthcare Conference (Miami Beach, FL)
Wednesday, June 12, 2024
Fireside Chat at 9:20 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Chief Financial Officer
jweilman@burnsmc.com
Danielle.cantey@inizioevoke.com

Frequently Asked Questions

When will Altimmune participate in the Jefferies Conference?

Altimmune will participate in the Jefferies Global Healthcare Conference on June 5, 2024.

What is Altimmune's focus area?

Altimmune specializes in developing peptide-based therapeutics for various conditions.

Where can I access the conference webcasts?

Webcasts can be accessed in the Events section of the Altimmune website.

What is pemvidutide used for?

Pemvidutide is developed as a treatment for obesity and MASH.

Tags: ALT Viatris Investor Conferences Healthcare Altimmune investor conferences biopharmaceuticals pemvidutide healthcare
Last updated: May 29, 2024

Conference Timeline

Nov 11, 2025
UBS Global Healthcare Conference
8:45 AM ET • Fireside Chat
Nov 18, 2025
Jefferies Global Healthcare
11:30 AM GMT • London